Literature DB >> 18976070

Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.

Edward F Chang1, Justin S Smith, Susan M Chang, Kathleen R Lamborn, Michael D Prados, Nicholas Butowski, Nicholas M Barbaro, Andrew T Parsa, Mitchel S Berger, Michael M McDermott.   

Abstract

OBJECT: Hemispheric low-grade gliomas (LGGs) have an unpredictable progression and overall survival (OS) profile. As a result, the objective in the present study was to design a preoperative scoring system to prognosticate long-term outcomes in patients with LGGs.
METHODS: The authors conducted a retrospective review with long-term follow-up of 281 adults harboring hemispheric LGGs (World Health Organization Grade II lesions). Clinical and radiographic data were collected and analyzed to identify preoperative predictors of OS, progression-free survival (PFS), and extent of resection (EOR). These variables were used to devise a prognostic scoring system.
RESULTS: The 5-year estimated survival probability was 0.86. Multivariate Cox proportional hazards modeling demonstrated that 4 factors were associated with lower OS: presumed eloquent location (hazard ratio [HR] 4.12, 95% confidence interval [CI] 1.71-10.42), Karnofsky Performance Scale score < or = 80 (HR 3.53, 95% CI 1.56-8.00), patient age > 50 years (HR 1.96, 95% CI 1.47-3.77), and tumor diameter > 4 cm (HR 3.43, 95% CI 1.43-8.06). A scoring system calculated from the sum of these factors (range 0-4) demonstrated risk stratification across study groups, with the following 5-year cumulative survival estimates: Scores 0-1, OS = 0.97, PFS = 0.76; Score 2, OS = 0.81, PFS = 0.49; and Scores 3-4, OS = 0.56, PFS = 0.18 (p < 0.001 for both OS and PFS, log-rank test). This proposed scoring system demonstrated a high degree of interscorer reliability (kappa = 0.86). Four illustrative cases are described.
CONCLUSIONS: The authors propose a simple and reliable scoring system that can be used to preoperatively prognosticate the degree of lesion resectability, PFS, and OS in patients with LGGs. The application of a standardized scoring system for LGGs should improve clinical decision-making and allow physicians to reliably predict patient outcome at the time of the original imaging-based diagnosis.

Entities:  

Mesh:

Year:  2008        PMID: 18976070     DOI: 10.3171/JNS/2008/109/11/0817

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  63 in total

1.  Scale to predict survival after surgery for recurrent glioblastoma multiforme.

Authors:  John K Park; Tiffany Hodges; Leopold Arko; Michael Shen; Donna Dello Iacono; Adrian McNabb; Nancy Olsen Bailey; Teri Nguyen Kreisl; Fabio M Iwamoto; Joohee Sul; Sungyoung Auh; Grace E Park; Howard A Fine; Peter McL Black
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

2.  Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.

Authors:  P Darvishi; P P Batchala; J T Patrie; L M Poisson; M-B Lopes; R Jain; C E Fadul; D Schiff; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-23       Impact factor: 3.825

Review 3.  Current concepts in the evaluation and management of WHO grade II gliomas.

Authors:  Joseph M Piepmeier
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

4.  Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery.

Authors:  Antonella Castellano; Lorenzo Bello; Caterina Michelozzi; Marcello Gallucci; Enrica Fava; Antonella Iadanza; Marco Riva; Giuseppe Casaceli; Andrea Falini
Journal:  Neuro Oncol       Date:  2011-10-20       Impact factor: 12.300

5.  Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Authors:  David A Reardon; Annick Desjardins; James J Vredenburgh; James E Herndon; April Coan; Sridharan Gururangan; Katherine B Peters; Roger McLendon; Sith Sathornsumetee; Jeremy N Rich; Eric S Lipp; Dorothea Janney; Henry S Friedman
Journal:  Cancer       Date:  2012-02-27       Impact factor: 6.860

6.  Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Authors:  Catherine Gozé; Marie Blonski; Guillaume Le Maistre; Luc Bauchet; Edouard Dezamis; Philippe Page; Pascale Varlet; Laurent Capelle; Bertrand Devaux; Luc Taillandier; Hugues Duffau; Johan Pallud
Journal:  Neuro Oncol       Date:  2014-05-20       Impact factor: 12.300

7.  MRI radiomics analysis of molecular alterations in low-grade gliomas.

Authors:  Ben Shofty; Moran Artzi; Dafna Ben Bashat; Gilad Liberman; Oz Haim; Alon Kashanian; Felix Bokstein; Deborah T Blumenthal; Zvi Ram; Tal Shahar
Journal:  Int J Comput Assist Radiol Surg       Date:  2017-12-21       Impact factor: 2.924

Review 8.  Management of low-grade glioma.

Authors:  Nader Pouratian; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

9.  Radiotherapy in low-grade glioma adult patients: a retrospective survival and neurocognitive toxicity analysis.

Authors:  Michela Buglione; Sara Pedretti; Stefano Gipponi; Alice Todeschini; Ludovica Pegurri; Loredana Costa; Laura Donadoni; Salvatore Grisanti; Marco Fontanella; Roberto Liserre; Fabio Facchetti; Alessandro Padovani; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

Review 10.  Low-grade gliomas.

Authors:  Jimmy Ruiz; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2009-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.